{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:03:48Z","timestamp":1793865828981,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.taap.2024.117135","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:10:41Z","timestamp":1730135441000},"page":"117135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis"],"prefix":"10.1016","volume":"492","author":[{"given":"Alexander R.","family":"Harmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Rolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2024.117135_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107498","article-title":"Virtual clinical QT exposure-response studies - a translational computational approach","volume":"126","author":"Aguado-Sierra","year":"2024","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2024.117135_bb0010","series-title":"ICH E14 CHMP\/ICH\/2\/04","article-title":"The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","author":"Anon","year":"2005"},{"key":"10.1016\/j.taap.2024.117135_bb0015","series-title":"ICH S7B CHMP\/ICH\/423\/02","article-title":"The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals","author":"Anon","year":"2005"},{"key":"10.1016\/j.taap.2024.117135_bb0020","series-title":"ICH. S7B\/E14 Q&A: Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential. Questions and Answers. 2022","author":"Anon","year":"2022"},{"key":"10.1016\/j.taap.2024.117135_bb0025","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1111\/bph.13940","article-title":"Predicting QRS and PR interval prolongations in humans using nonclinical data","volume":"174","author":"Bergenholm","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ccep.2016.01.004","article-title":"Cardiac delayed rectifier potassium channels in health and disease","volume":"8","author":"Chen","year":"2016","journal-title":"Card Electrophysiol. Clin."},{"key":"10.1016\/j.taap.2024.117135_bb0035","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jcph.1844","article-title":"QT prolongation risk assessment in oncology: lessons learned from small-molecule new drug applications approved during 2011-2019","volume":"61","author":"Cohen-Rabbie","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0040","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/jcph.2309","article-title":"The new S7B\/E14 Q&a Document Provides Additional Opportunities to replace the thorough QT study","volume":"63","author":"Darpo","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/cts.12527","article-title":"Reverse translation of US Food and Drug Administration reviews of oncology new molecular entities approved in 2011-2017: lessons learned for anticancer drug development","volume":"11","author":"Faucette","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.taap.2024.117135_bb0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2024.117135_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.270","article-title":"Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation","volume":"4","author":"Gotta","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.taap.2024.117135_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"On the relationship between block of the cardiac Na(+) channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.008130","article-title":"Balance between rapid delayed rectifier K(+) current and late Na(+) current on ventricular repolarization: an effective antiarrhythmic target?","volume":"13","author":"Hegyi","year":"2020","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.taap.2024.117135_bb0070","doi-asserted-by":"crossref","DOI":"10.1063\/1.5132618","article-title":"In silico models for evaluating proarrhythmic risk of drugs","volume":"4","author":"Hwang","year":"2020","journal-title":"APL Bioeng."},{"key":"10.1016\/j.taap.2024.117135_bb0075","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clpt.2005.02.004","article-title":"A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data","volume":"77","author":"Jonker","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2024.117135_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfx236","article-title":"Predicting drug safety and communicating risk: benefits of a Bayesian approach","volume":"162","author":"Lazic","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2024.117135_bb0085","doi-asserted-by":"crossref","first-page":"107524","DOI":"10.1016\/j.vascn.2024.107524","article-title":"Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions","volume":"128","author":"Leishman","year":"2024","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2024.117135_bb0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2024.117135_bb0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.12793\/tcp.2019.27.1.12","article-title":"Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative","volume":"27","author":"Park","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2024.117135_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2024.117135_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114961","article-title":"A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm","volume":"394","author":"Ridder","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2024.117135_bb0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2024.117135_bb0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2024.117135_bb0130","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1038\/s41467-023-40064-9","article-title":"A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs","volume":"14","author":"Sutherland","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2024.117135_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicting drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2024.117135_bb0140","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2024.117135_bb0145","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1152\/physrev.00024.2019","article-title":"Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior","volume":"101","author":"Varro","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.taap.2024.117135_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10543406.2024.2365972","article-title":"Meta-analysis application to hERG safety evaluation in clinical trials. 2024","volume":"14","author":"Zhao","year":"2024","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.taap.2024.117135_bb0155","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fphar.2019.01643","article-title":"Blinded in silico drug trial reveals the minimum set of ion channels for Torsades de pointes risk assessment","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2400334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2400334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T09:12:44Z","timestamp":1731402764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X2400334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"alternative-id":["S0041008X2400334X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.117135","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.117135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117135"}}